• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Percent of CDER employees who reported 100% of their time during the quarter

Dictionary: Activity Time Reporting is a reporting tool used to manage CDER's core business activities. All CDER employees, except overhead organizations and secretarial/clerical employees, are required to report 100% of their time activities during biannual reporting period. FDA bases its approval of funding and personnel (FTE) increases in CDER's mission critical activities and initiatives, including PDUFA (Prescription Drug User Fee Act). Activity Time Reporting also allows CDER to review of the costs of activities and projects, reset User Fees for drugs and biologics, monitor progress of work, and manage performance.


These measures have been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research.

Fiscal Year - 2011

Skip graphic and jump to text data

TimeTargetPercent
Oct - Dec 2010N/A100
Jan - Mar 2011N/AN/A
Apr – Jun 2011N/A100
Jul - Sep 2011N/AN/A

Number of CDER employees who reported 100% of their time during the quarter

Fiscal Year - 2011
Skip graphic and jump to text data.

TimeTargetNumber
Oct – Dec 2010N/A2,782
Jan - Mar 2011N/AN/A
Apr - Jun 2011N/A2,837
Jul - Sep 2011N/AN/A

Number of CDER employees required to report their time during the quarter

Fiscal Year - 2011
Skip graphic and jump to text data.

TimeTargetNumber
Oct - Dec 2010N/A2,782
Jan - Mar 2011N/AN/A
Apr - Jun 2011N/A2,837
Jul - Sep 2011N/AN/A

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.